Small-cap biotechnology company Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has gained publicity recently due to its attempts to develop treatments for some of the world’s most common diseases, in particular Alzheimer’s, Parkinson’s and Huntington’s. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) in last trading activity ended up at $10.10 with day range of $7.80 – $10.74. Company weekly performance is 10.50% while its quarterly performance stands at 137.09%.
Actavis plc Ordinary Shares (NYSE:ACT) will pay $89.48 per share, comprised of $26.04 in cash and 0.3306 of an Actavis share. The price represents a premium of 25% over Forest Laboratories, Inc.(NYSE:FRX)’s close on Friday of $71.39.The merger would create a company with combined forecast revenues of $15B in 2015 and free cash flow of over $4B. On Tuesday shares of Actavis plc Ordinary Shares (NYSE:ACT) opened at $205.04 and closed at $201.47.
Blucora Inc (NASDAQ:BCOR) was plummeting 15.54% to $20.02 shortly after noon on Tuesday on higher-than-usual volume. On last trading day Blucora Inc (NASDAQ:BCOR) ended up -8.44% lower to close at $21.70 while trading in the range of $19.43 – $21.90. Blucora Inc (NASDAQ:BCOR) monthly performance is -21.97%. Its return on assets is 3.70% while return on investment is 4.60%.
Astrazeneca PLC (ADR) (NYSE:AZN) will begin trading ex-dividend on February 19, 2014. A cash dividend payment of $1.9 per share is scheduled to be paid on March 24, 2014. Shareholders who purchased AZN stock prior to the ex-dividend date are eligible for the cash dividend payment. AstraZeneca plc (ADR) (NYSE:AZN) shares advanced 1.11% on last trading day. Company has a market capitalization of 85.86 B. In last trading activity company’s stock closed at $68.15 while opening price was $68.01.